Katia Abarca

7PUBLICATIONS
66CO-AUTHORS
Infant and child healthMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersAgricultural molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 16, 2022
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.

Jorge A Soto, Felipe Melo-González, Cristián Gutierrez-Vera

|Oct 13, 2022
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial.

Nicolás M S Gálvez, Gaspar A Pacheco, Bárbara M Schultz

|Aug 10, 2022
A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.

Bárbara M Schultz, Felipe Melo-González, Luisa F Duarte

|Jul 27, 2022
Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial.

Katia Abarca, Carolina Iturriaga, Marcela Urzúa

|Apr 20, 2022
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern.

Bárbara M Schultz, Felipe Melo-González, Luisa F Duarte

|Apr 20, 2022
Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial.

Susan M Bueno, Katia Abarca, Pablo A González

Pageof 2

Frequent Collaborators

6 joint publications

Susan M Bueno

5 joint publications

Alexis M Kalergis

5 joint publications

Gaspar A Pacheco

5 joint publications

Pablo A González